Airsonett is a research based medical technology company. Its unique technology leads the development of prophylactic treatment of allergic asthma (Protexo) and infection control in operation theatres (Opragon).

Airsonett has an extensive portfolio of patents and is investing heavily in clinical research and product development.
With strong owners, such as SEB Venture Capital and Industrifonden, Airsonett is now forming a whole new medical technology industry at its headquarters in Ängelholm, Sweden.

The company started in the mid-1990s as a part of AirSon AB, a well-known player in the clean room industry. The Temperature controlled Laminar Airflow (TLA) technique is developed from the industrial clean room technology.
In 2000 Airsonett AB was established as an entity of its own.